Arcutis Biotherapeutics, Inc.
Символ: ARQT
NASDAQ
8.6
USDПазарна цена днес
-3.0415
Съотношение P/E
0.0000
Коефициент PEG
988.75M
MRK Cap
- 0.00%
Доходност на DIV
Arcutis Biotherapeutics, Inc. (ARQT) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1100.97 | 272.8 | 409.6 | 387.1 | |||||||
balance-sheet.row.short-term-investments | 717.66 | 183.5 | 355.9 | 290.6 | |||||||
balance-sheet.row.net-receivables | 75.2 | 25.8 | 8.5 | 0.4 | |||||||
balance-sheet.row.inventory | 46.07 | 13.1 | 7.5 | 1.2 | |||||||
balance-sheet.row.other-current-assets | 63.5 | 18.7 | 10.6 | 14.2 | |||||||
balance-sheet.row.total-current-assets | 1288.52 | 330.4 | 437.4 | 402.8 | |||||||
balance-sheet.row.property-plant-equipment-net | 17.21 | 3.9 | 4.6 | 5.3 | |||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 26.88 | 6.4 | 7.2 | 0 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 26.88 | 6.4 | 7.2 | 0 | |||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.other-non-current-assets | 1.87 | 0.6 | 0.1 | 0.1 | |||||||
balance-sheet.row.total-non-current-assets | 45.95 | 10.9 | 11.9 | 5.4 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 1334.47 | 341.4 | 449.3 | 408.2 | |||||||
balance-sheet.row.account-payables | 54.81 | 12 | 8.8 | 7.4 | |||||||
balance-sheet.row.short-term-debt | 2.82 | 0.7 | 0.7 | 0.4 | |||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.long-term-debt-total | 812.38 | 201.8 | 201.9 | 77.1 | |||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 104.61 | 33.9 | 28.3 | 25.5 | |||||||
balance-sheet.row.total-non-current-liabilities | 816.61 | 206 | 201.9 | 77.1 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 16.73 | 3.4 | 4.8 | 5.2 | |||||||
balance-sheet.row.total-liab | 978.85 | 252.7 | 239.7 | 110.5 | |||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.common-stock | 0.03 | 0 | 0 | 0 | |||||||
balance-sheet.row.retained-earnings | -3568.24 | -981.9 | -719.8 | -408.3 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.89 | 0 | -1.1 | -0.3 | |||||||
balance-sheet.row.other-total-stockholders-equity | 3924.73 | 1070.6 | 930.4 | 706.2 | |||||||
balance-sheet.row.total-stockholders-equity | 355.62 | 88.7 | 209.6 | 297.7 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1334.47 | 341.4 | 449.3 | 408.2 | |||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-equity | 355.62 | 88.7 | 209.6 | 297.7 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 1334.47 | - | - | - | |||||||
Total Investments | 717.66 | 183.5 | 355.9 | 290.6 | |||||||
balance-sheet.row.total-debt | 818.58 | 205.9 | 202.5 | 77.6 | |||||||
balance-sheet.row.net-debt | 435.26 | 116.6 | 148.9 | -18.9 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -262.14 | -262.1 | -311.5 | -206.4 | |||||||
cash-flows.row.depreciation-and-amortization | 1.52 | 1.9 | 0.9 | 0.5 | |||||||
cash-flows.row.deferred-income-tax | -19.69 | 19.8 | 0 | 3.5 | |||||||
cash-flows.row.stock-based-compensation | 38.81 | 38.8 | 32.7 | 23.9 | |||||||
cash-flows.row.change-in-working-capital | -23.5 | -23.5 | -10.2 | 3.6 | |||||||
cash-flows.row.account-receivables | -17.35 | -17.3 | -8.5 | 0 | |||||||
cash-flows.row.inventory | -5.62 | -5.6 | -7.5 | 0 | |||||||
cash-flows.row.account-payables | 3.15 | 3.2 | 1.6 | 0.2 | |||||||
cash-flows.row.other-working-capital | -3.68 | -3.7 | 4.2 | 3.4 | |||||||
cash-flows.row.other-non-cash-items | 17.94 | -21.9 | 30.3 | 0.3 | |||||||
cash-flows.row.net-cash-provided-by-operating-activities | -247.06 | 0 | 0 | 0 | |||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.43 | -0.4 | -23.3 | -1 | |||||||
cash-flows.row.acquisitions-net | -180.66 | 0 | 22.9 | 75 | |||||||
cash-flows.row.purchases-of-investments | -225.84 | -225.8 | -415.4 | -292.5 | |||||||
cash-flows.row.sales-maturities-of-investments | 406.5 | 406.5 | 351.5 | 217.6 | |||||||
cash-flows.row.other-investing-activites | 180.66 | 0 | -22.9 | -75 | |||||||
cash-flows.row.net-cash-used-for-investing-activites | 180.23 | 180.2 | -87.2 | -76 | |||||||
cash-flows.row.debt-repayment | 0 | 0 | -122.8 | -72.3 | |||||||
cash-flows.row.common-stock-issued | 100.26 | 101.3 | 176 | 207.5 | |||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 12.5 | 0.8 | |||||||
cash-flows.row.dividends-paid | 0 | 0 | -122.8 | -72.3 | |||||||
cash-flows.row.other-financing-activites | 101.32 | 5.6 | 358.9 | 218.3 | |||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 101.32 | 101.3 | 301.8 | 281.9 | |||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.05 | -0.1 | 0 | 0 | |||||||
cash-flows.row.net-change-in-cash | 34.45 | 34.4 | -43.1 | 31.4 | |||||||
cash-flows.row.cash-at-end-of-period | 386.09 | 89.3 | 54.9 | 98 | |||||||
cash-flows.row.cash-at-beginning-of-period | 351.64 | 54.9 | 98 | 66.6 | |||||||
cash-flows.row.operating-cash-flow | -247.06 | -247.1 | -257.7 | -174.6 | |||||||
cash-flows.row.capital-expenditure | -0.43 | -0.4 | -23.3 | -1 | |||||||
cash-flows.row.free-cash-flow | -247.49 | -247.5 | -281 | -175.6 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 59.61 | 59.6 | 3.7 | 0 | |||||||
income-statement-row.row.cost-of-revenue | 5.18 | 6.1 | 0.8 | 0.8 | |||||||
income-statement-row.row.gross-profit | 54.42 | 53.5 | 2.9 | -0.8 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 110.58 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 235.81 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | -50.87 | - | - | - | |||||||
income-statement-row.row.other-expenses | 11.72 | 11.8 | 5.8 | 0.2 | |||||||
income-statement-row.row.operating-expenses | 295.52 | 294.6 | 304.6 | 206.5 | |||||||
income-statement-row.row.cost-and-expenses | 300.71 | 300.7 | 305.3 | 206.5 | |||||||
income-statement-row.row.interest-income | 12.9 | 0 | 9.8 | 0.2 | |||||||
income-statement-row.row.interest-expense | 29.71 | 29.7 | 15.7 | 0 | |||||||
income-statement-row.row.selling-and-marketing-expenses | -50.87 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | -3.08 | -17.9 | -9.8 | 0.2 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | 11.72 | 11.8 | 5.8 | 0.2 | |||||||
income-statement-row.row.total-operating-expenses | -3.08 | -17.9 | -9.8 | 0.2 | |||||||
income-statement-row.row.interest-expense | 29.71 | 29.7 | 15.7 | 0 | |||||||
income-statement-row.row.depreciation-and-amortization | 6.7 | 1.9 | 5.8 | 0.5 | |||||||
income-statement-row.row.ebitda-caps | -231.67 | - | - | - | |||||||
income-statement-row.row.operating-income | -241.1 | -241.1 | -301.6 | -206.5 | |||||||
income-statement-row.row.income-before-tax | -259.09 | -259 | -311.5 | -206.4 | |||||||
income-statement-row.row.income-tax-expense | 12.77 | 3.1 | 9.8 | -0.5 | |||||||
income-statement-row.row.net-income | -261.78 | -262.1 | -321.3 | -205.9 |
Често задавани въпроси
Какво е Arcutis Biotherapeutics, Inc. (ARQT) общи активи?
Arcutis Biotherapeutics, Inc. (ARQT) общите активи са 341365000.000.
Какъв е годишният приход на предприятието?
Годишните приходи са 51635000.000.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е -2.673.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е -2.673.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е -4.392.
Какъв е общият приход на предприятието?
Общият приход е -4.045.
Каква е Arcutis Biotherapeutics, Inc. (ARQT) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е -262140000.000.
Какъв е общият дълг на фирмата?
Общият дълг е 205916000.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 294589000.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са 89323000.000.